cbdMD Announces Hiring of Dr. Sibyl Swift as VP of Scientific & Regulatory Affairs
April 29 2021 - 1:45PM
Business Wire
cbdMD, Inc. (NYSE American: YCBD, YCBDpA) (the “Company”), one
of the leading, and most highly trusted and recognized cannabidiol
(CBD) brands, announced today that it has hired Dr. Sibyl Swift, as
Vice President for Scientific & Regulatory Affairs. The Company
previously announced in February 2020 that Dr. Swift had been
engaged as a regulatory consultant to oversee the Company’s
regulatory initiatives. She was also recently named as co-Chair of
cbdMD Therapeutics, along with the company’s General Counsel, Lance
Blundell. Prior to joining cbdMD, Dr. Swift was the Senior VP for
Scientific & Regulatory Affairs at the Natural Products
Association (NPA) where she led the association’s work in Codex,
the Supplement Safety & Compliance Initiative (SSCI), and FDA
policy. Prior to her time at the NPA, Dr. Swift was the associate
director for research and strategy at the US Food and Drug
Administration (FDA), where she directed the Office of Dietary
Supplement Programs research agenda and worked closely on office
policy and enforcement.
Dr. Swift will oversee the Company’s GMP compliance, internal
product quality and safety initiatives, and direct the Company’s
scientific work performed in support of world-wide regulatory
submissions and claims substantiation. These efforts, and her
outside work with standards setting organizations, such as AOAC’s
CASP group demonstrates the Company’s continued commitment to
providing its consumers with products that meet the highest
regulatory standards for quality and safety.
“We have had the good fortune to be able to work with Dr. Swift
over the past several months as she has guided cbdMD in its Novel
Food Applications (“Applications”) with the United Kingdom’s Food
Standards Agency (“FSA”) and the European Food Safety Authority
(“EFSA”). Specifically, Dr. Swift helped with the Applications’
detailed analysis of the quality and stability of our products, our
hemp sourcing and extraction controls, our labelling and testing
requirements, and the underlying intake and toxicological data
related to the safe consumption of the proprietary cannabinoid
blend ingredients in our cbdMD product line. We are excited that
Dr. Swift has joined our team at cbdMD in a full time capacity,”
said Martin Sumichrast, Chairman & Co-CEO of cbdMD, Inc.
About cbdMD, Inc.
cbdMD, Inc. is one of the leading and most highly trusted and
most recognized cannabidiol (CBD) brands with a comprehensive line
of U.S. produced, THC-free1 CBD products. Our cbdMD brand currently
includes over 130 SKUs of high-grade, premium CBD products
including CBD tinctures, CBD gummies, CBD topicals, CBD capsules,
CBD bath bombs, CBD bath salts, CBD sleep aids and CBD drink mixes.
Our Paw CBD brand of pet products includes over 45 SKUs of
veterinarian-formulated products including tinctures, chews,
topicals products in varying strengths, and our CBD Botanicals
brand of beauty and skincare products features 15 SKUs, including
facial oil and serum, toners, moisturizers, clear skin, facial
masks, exfoliants and body care. Please visit www.cbdMD.com, follow
cbdMD on Instagram and Facebook, or visit one of the 6,000 retail
outlets that carry cbdMD products. To learn more about cbdMD and
their comprehensive line of U.S. grown, THC-free1 CBD oil products,
please visit www.cbdmd.com.
Forward-Looking Statements
This press release contains certain forward-looking statements
that are based upon current expectations and involve certain risks
and uncertainties within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995. Such forward-looking statements can
be identified by the use of words such as ''should,'' ''may,''
''intends,'' ''anticipates,'' ''believes,'' ''estimates,''
''projects,'' ''forecasts,'' ''expects,'' ''plans,'' and
''proposes.'' These forward-looking statements are not guarantees
of future performance and are subject to risks, uncertainties, and
other factors, some of which are beyond our control and difficult
to predict. You are urged to carefully review and consider any
cautionary statements and other disclosures, including the
statements made under the heading "Risk Factors" in cbdMD, Inc.'s
Annual Report on Form 10-K for the fiscal year ended September 30,
2020 as filed with the Securities and Exchange Commission (the
"SEC") on December 22, 2020 and our other filings with the SEC. All
forward-looking statements involve significant risks and
uncertainties that could cause actual results to differ materially
from those in the forward-looking statements, many of which are
generally outside the control of cbdMD, Inc. and are difficult to
predict. cbdMD, Inc. does not undertake any duty to update any
forward-looking statements except as may be required by law. The
information which appears on our websites and our social media
platforms, including, but not limited to, Instagram and Facebook,
is not part of this press release.
1 THC-free is defined as below the level of detection using
validated scientific analytical tools.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210429005918/en/
PR: 5W Public Relations cbdMD@5wpr.com (212) 999-5585
Investors: cbdMD, Inc., John Weston, Director of Investor
Relations John.Weston@cbdMD.com (704) 249-9515
cbdMD (AMEX:YCBD)
Historical Stock Chart
From Apr 2024 to May 2024
cbdMD (AMEX:YCBD)
Historical Stock Chart
From May 2023 to May 2024